Optimizing protocols for monitoring in vivo replication of a novel chimeric Marek’s Disease vaccine with an insertion of the Long Terminal Repeat of Reticuloendotheliosis Virus in the CVI988 Strain genome (CVI-LTR)
Monitoring Marek's disease (MD) vaccination is routinely done by evaluating the load of MD vaccine in the feather pulp (FP) between 7 and 10 days of age. However, attempts in our laboratory to detect a novel CVI-LTR vaccine in the FP samples from commercial flocks failed. The objective of this...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Published: |
Taylor and Francis
2024
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/112120/ |
| _version_ | 1848865862494191616 |
|---|---|
| author | Faiz, Nik M. Cortes, Aneg L. Phang, Yuen-fun Gimeno, Isabel M. |
| author_facet | Faiz, Nik M. Cortes, Aneg L. Phang, Yuen-fun Gimeno, Isabel M. |
| author_sort | Faiz, Nik M. |
| building | UPM Institutional Repository |
| collection | Online Access |
| description | Monitoring Marek's disease (MD) vaccination is routinely done by evaluating the load of MD vaccine in the feather pulp (FP) between 7 and 10 days of age. However, attempts in our laboratory to detect a novel CVI-LTR vaccine in the FP samples from commercial flocks failed. The objective of this study was to evaluate the most suitable tissue and age to monitor CVI-LTR vaccination. We used two different commercial CVI988 vaccines as controls. One hundred and sixty 1-day-old commercial brown layers were vaccinated with either CVI-LTR, CVI988-A, CVI988-B or remained unvaccinated. Samples of the spleen, thymus, and bursa were collected at 3, 4, 5, and 6 days of age and samples of FP were collected at 7 and 21 days for DNA isolation. Our results showed that CVI-LTR replicated earlier than CVI988 vaccines in the lymphoid organs but was not detected in the FP at either 7 or at 21 days of age. We also confirmed that either the spleen or thymus collected at 4-6 days was a suitable sample to monitor CVI-LTR vaccination in commercial flocks. Finally, we evaluated the load of oncogenic MDV DNA in five commercial flocks that were vaccinated with either CVI-LTR + rHVT or CVI988-A + rHVT. The load of oncogenic MDV DNA was evaluated at 21 days in the FP in 20 chickens per group. Our results demonstrated that CVI-LTR was more successful in reducing oncogenic MDV DNA at 21 days of age than the CVI988-A strain.RESEARCH HIGHLIGHTSCVI-LTR replicates in the thymus and spleen earlier than CVI988.CVI-LTR replicates in lymphoid organs but it cannot be detected in feather pulp.CVI-LTR reduced the load of oncogenic MDV DNA more efficiently than CVI988. |
| first_indexed | 2025-11-15T14:11:27Z |
| format | Article |
| id | upm-112120 |
| institution | Universiti Putra Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-15T14:11:27Z |
| publishDate | 2024 |
| publisher | Taylor and Francis |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | upm-1121202024-10-23T03:07:20Z http://psasir.upm.edu.my/id/eprint/112120/ Optimizing protocols for monitoring in vivo replication of a novel chimeric Marek’s Disease vaccine with an insertion of the Long Terminal Repeat of Reticuloendotheliosis Virus in the CVI988 Strain genome (CVI-LTR) Faiz, Nik M. Cortes, Aneg L. Phang, Yuen-fun Gimeno, Isabel M. Monitoring Marek's disease (MD) vaccination is routinely done by evaluating the load of MD vaccine in the feather pulp (FP) between 7 and 10 days of age. However, attempts in our laboratory to detect a novel CVI-LTR vaccine in the FP samples from commercial flocks failed. The objective of this study was to evaluate the most suitable tissue and age to monitor CVI-LTR vaccination. We used two different commercial CVI988 vaccines as controls. One hundred and sixty 1-day-old commercial brown layers were vaccinated with either CVI-LTR, CVI988-A, CVI988-B or remained unvaccinated. Samples of the spleen, thymus, and bursa were collected at 3, 4, 5, and 6 days of age and samples of FP were collected at 7 and 21 days for DNA isolation. Our results showed that CVI-LTR replicated earlier than CVI988 vaccines in the lymphoid organs but was not detected in the FP at either 7 or at 21 days of age. We also confirmed that either the spleen or thymus collected at 4-6 days was a suitable sample to monitor CVI-LTR vaccination in commercial flocks. Finally, we evaluated the load of oncogenic MDV DNA in five commercial flocks that were vaccinated with either CVI-LTR + rHVT or CVI988-A + rHVT. The load of oncogenic MDV DNA was evaluated at 21 days in the FP in 20 chickens per group. Our results demonstrated that CVI-LTR was more successful in reducing oncogenic MDV DNA at 21 days of age than the CVI988-A strain.RESEARCH HIGHLIGHTSCVI-LTR replicates in the thymus and spleen earlier than CVI988.CVI-LTR replicates in lymphoid organs but it cannot be detected in feather pulp.CVI-LTR reduced the load of oncogenic MDV DNA more efficiently than CVI988. Taylor and Francis 2024 Article PeerReviewed Faiz, Nik M. and Cortes, Aneg L. and Phang, Yuen-fun and Gimeno, Isabel M. (2024) Optimizing protocols for monitoring in vivo replication of a novel chimeric Marek’s Disease vaccine with an insertion of the Long Terminal Repeat of Reticuloendotheliosis Virus in the CVI988 Strain genome (CVI-LTR). Avian Pathology, 53 (4). pp. 303-311. ISSN 0307-9457; ESSN: 1465-3338 https://doi.org/10.1080/03079457.2024.2324930 10.1080/03079457.2024.2324930 |
| spellingShingle | Faiz, Nik M. Cortes, Aneg L. Phang, Yuen-fun Gimeno, Isabel M. Optimizing protocols for monitoring in vivo replication of a novel chimeric Marek’s Disease vaccine with an insertion of the Long Terminal Repeat of Reticuloendotheliosis Virus in the CVI988 Strain genome (CVI-LTR) |
| title | Optimizing protocols for monitoring in vivo replication of a novel chimeric Marek’s Disease vaccine with an insertion of the Long Terminal Repeat of Reticuloendotheliosis Virus in the CVI988 Strain genome (CVI-LTR) |
| title_full | Optimizing protocols for monitoring in vivo replication of a novel chimeric Marek’s Disease vaccine with an insertion of the Long Terminal Repeat of Reticuloendotheliosis Virus in the CVI988 Strain genome (CVI-LTR) |
| title_fullStr | Optimizing protocols for monitoring in vivo replication of a novel chimeric Marek’s Disease vaccine with an insertion of the Long Terminal Repeat of Reticuloendotheliosis Virus in the CVI988 Strain genome (CVI-LTR) |
| title_full_unstemmed | Optimizing protocols for monitoring in vivo replication of a novel chimeric Marek’s Disease vaccine with an insertion of the Long Terminal Repeat of Reticuloendotheliosis Virus in the CVI988 Strain genome (CVI-LTR) |
| title_short | Optimizing protocols for monitoring in vivo replication of a novel chimeric Marek’s Disease vaccine with an insertion of the Long Terminal Repeat of Reticuloendotheliosis Virus in the CVI988 Strain genome (CVI-LTR) |
| title_sort | optimizing protocols for monitoring in vivo replication of a novel chimeric marek’s disease vaccine with an insertion of the long terminal repeat of reticuloendotheliosis virus in the cvi988 strain genome (cvi-ltr) |
| url | http://psasir.upm.edu.my/id/eprint/112120/ http://psasir.upm.edu.my/id/eprint/112120/ http://psasir.upm.edu.my/id/eprint/112120/ |